ABBV

Over the past six months, AbbVie's stock price increased by approximately 39.74%, driven by positive earnings reports and clinical trial data. Key events include beating Wall Street's revenue expectations in Q2 CY2026 with sales up 10.2% year-on-year to $16.99 billion and non-GAAP profit of $3.65 per share, leading to an upward revision of full-year guidance. Q1 FY26 earnings reported EPS of $2.65 and revenue of $15.00 billion, both inline with estimates. In October 2026, AbbVie announced positive clinical trial data for two pipeline candidates, including Telisotuzumab Adizutecan receiving two Breakthrough Therapy Designations from the U.S. FDA for CRC and NSCLC. Also in October 2026, Epcoritamab, in partnership with Genmab, demonstrated significant improvement in progression-free survival in newly diagnosed Diffuse Large B-Cell Lymphoma, and long-term data for RINVOQ showed continued repigmentation in non-segmental vitiligo. Analysts have given AbbVie stock a consensus 'buy' rating.